Literature DB >> 24041356

Priority preferences: "end of life" does not matter, but total life does.

Jan Abel Olsen1.   

Abstract

There is increasing evidence that the social value of an incremental health gain depends on patient characteristics, such as their age and their prognosis. This article presents an analytical framework to illustrate how a disease splits our life expectancy into 1) past health (age), 2) prognosis untreated, 3) gain from treatment, and 4) incurable loss. A Norwegian population sample was asked to make pairwise choices and prioritize hypothetical patients who differed in terms of age (30, 50, and 70 years old), remaining lifetime without treatment (1, 3, and 10 years), and increase in remaining lifetime with treatment (1 month, 3 months, 1 year, and 3 years). Their preferences reveal strong support for the "fair innings" argument that total lifetime inequalities should be reduced. Differences in patients' remaining lifetime without treatment did not matter, implying little support for the "end-of-life" argument that a short life expectancy makes patients entitled to preferential treatment.
Copyright © 2013, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc.

Entities:  

Keywords:  priority preferences; “end of life”; “fair innings.”

Mesh:

Year:  2013        PMID: 24041356     DOI: 10.1016/j.jval.2013.06.002

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  7 in total

1.  Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.

Authors:  S Olofsson; U-G Gerdtham; L Hultkrantz; U Persson
Journal:  Eur J Health Econ       Date:  2017-08-12

2.  Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss.

Authors:  Ulrikke J V Hernæs; Kjell A Johansson; Trygve Ottersen; Ole F Norheim
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

3.  When is it too expensive? Cost-effectiveness thresholds and health care decision-making.

Authors:  Werner Brouwer; Pieter van Baal; Job van Exel; Matthijs Versteegh
Journal:  Eur J Health Econ       Date:  2019-03

4.  Extending life for people with a terminal illness: a moral right and an expensive death? Exploring societal perspectives.

Authors:  Neil McHugh; Rachel M Baker; Helen Mason; Laura Williamson; Job van Exel; Rohan Deogaonkar; Marissa Collins; Cam Donaldson
Journal:  BMC Med Ethics       Date:  2015-03-07       Impact factor: 2.652

Review 5.  Prioritizing Communication in the Provision of Palliative Care for the Trauma Patient.

Authors:  Mackenzie Cook; David Zonies; Karen Brasel
Journal:  Curr Trauma Rep       Date:  2020-10-29

6.  Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases.

Authors:  Frode Lindemark; Ole Frithjof Norheim; Kjell Arne Johansson
Journal:  Cost Eff Resour Alloc       Date:  2014-07-23

7.  Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment.

Authors:  Liesbet van de Wetering; Job van Exel; Ana Bobinac; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2015-12       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.